Cambridge Research Biochemicals (CRB), which is based in the North East of England and supplies peptides and antibodies for life science research and development, has signed a licence agreement with Edinburgh Innovations, the Innovation Management Service for The University of Edinburgh.
Under the new agreement, CRB will be permitted to label both custom made and catalogue peptides with novel dyes developed by a research team from The University of Edinburgh, School of Clinical Sciences, led by the Principal Investigator Dr Marc Vendrell.
Dr Vendrell worked in collaboration with academic partners at the University of Barcelona and IRB Barcelona, led by Professor Rodolfo Lavilla, and The University of Manchester’s Professor Nick Read to invent the technology.